A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Pirfenidone (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ASCEND
  • Sponsors InterMune
  • Most Recent Events

    • 12 Sep 2017 Resultsof a pooled CAPACITY and ASCEND trials published in the Roche Media Release
    • 24 May 2017 Results (n=1247) of pooled analysis comparing the effect of pirfenidone on progression-free survival (PFS) using a pre-specified PFS definition versus a novel definition of PFS using data from phase III trials (ASCEND or CAPACITY), presented at the 113th International Conference of the American Thoracic Society.
    • 24 May 2017 Results of a subgroup analysis in patients stratified by GAP stage and FVC value from three randomised trials (ASCEND and CAPACITY trials; n=1247), presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top